LFA-REAL™ (Rapid Evaluation of Activity in Lupus) is a new, first-of-its-kind tool to monitor lupus disease activity, addressing both the needs and concerns of providers and people with lupus.
We Lead Scientific Initiatives to Address Barriers in Lupus Drug Development
The Foundation's Medical-Scientific Advisory Council, composed of lupus experts from many specialties, continually assesses the state of lupus research to identify the most urgent issues facing the field. We convene scientific community leaders to identify solutions and marshal resources to implement projects that have the potential to overcome barriers, accelerate clinical research, and encourage pharmaceutical and biotechnology companies to develop new therapies for lupus.
Roadmap to Securing New Lupus Treatments
In 2009, the Foundation commissioned a nine-month study by the nationally recognized health policy research organization, The Lewin Group, to examine barriers to lupus drug development. The report, "Overcoming Barriers to Drug Development in Lupus," is the first to detail obstacles and provide recommendations on how to overcome them.
Since the report was issued, the Foundation has been working to bring key stakeholders together to address each barrier. These efforts have resulted in a collection of far-reaching initiatives which are linked below.
The initiative provides insight to improve clinical trial design so we can have the arsenal of treatments needed for people living with lupus.
The first global definition of a lupus flare is a valuable tool for clinicians and investigators in evaluating the effectiveness of a new treatment.
The LFA POINT has become the gold-standard web-based training tool on lupus disease assessment instruments. Consistent use of the instruments will help improve the quality of studies on new therapies.